DOCSLIB.ORG

NIRMA UNIVERSITY Institute of Pharmacy (B. Pharm) (Semester - I)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NIRMA UNIVERSITY Institute of Pharmacy (B. Pharm) (Semester - I) Nirma University Institute of Pharmacy Programme: Bachelor of Pharmacy 0 NIRMA UNIVERSITY Institute of Pharmacy (B. Pharm) (Semester - I) L T P C 3 1 4 Course Code BP101T Course Title Human Anatomy and Physiology I- Theory Scope: This subject is designed to impart fundamental knowledge on the structure and functions of the various systems of the human body. It also helps in understanding homeostatic mechanisms. The subject provides the basic knowledge required to understand various disciplines of pharmacy. Objectives: Upon completion of this course the student should be able to - 1. Explain gross morphology, structure and functions of various organs of the human body. 2. Describe various homeostatic mechanisms and their imbalances. 3. Identify various tissues and organs of different systems of human body. 4. Perform several experiments related to special senses and nervous system. 5. Appreciate coordinated working pattern of different organs of each system. Course Learning Outcomes (CLO): At the end of the course, students will be able to - 1. Identify the structure, location of cell, tissues, muscles and various organs of the body. 2. Remember various feedback mechanisms that help to regulate physiological processes. 3. Describe anatomy, physiology and functions of integumentary, skeletal and nervous system. 4. Explain structure and functions of various endocrine glands and list their disorders. 5. Assess normal and abnormal functioning of various sensory organs. Syllabus: Teaching hours: 45 Hours UNIT I 10 Hours • Introduction to human body Definition and scope of anatomy and physiology, levels of structural organization and body systems, basic life processes, homeostasis, basic anatomical terminology. • Cellular level of organization Structure and functions of cell, transport across cell membrane, cell division, cell junctions. General principles of cell commun ication, intracellular signaling pathway activation by 1 extracellular signal molecule, Forms of intracellular signaling: a) Contact-dependent b) Paracrine c) Synaptic d) Endocrine • Tissue level of organization Classification of tissues, structure, location and functions of epithelial, muscular and nervous and connective tissues. UNIT II 10 Hours • Integumentary system Structure and functions of skin • Skeletal system Divisions of skeletal system, types of bone, salient features and functions of bones of axial and appendicular skeletal system Organization of skeletal muscle, physiology of muscle contraction, neuromuscular junction UNIT III 10 Hours • Nervous system Organization of nervous system, neuron, neuroglia, classification and properties of nerve fibre, electrophysiology, action potential, nerve impulse, receptors, synapse, neurotransmitters. Central nervous system: Meninges, ventricles of brain and cerebrospinal fluid. Structure and functions of brain (cerebrum, brain stem, cerebellum), spinal cord (gross structure, functions of afferent and efferent nerve tracts, reflex activity) UNIT IV 08 Hours • Peripheral nervous system: Classification of peripheral nervous system: Structure and functions of sympathetic and parasympathetic nervous system. Origin and functions of spinal and cranial nerves. • Special senses Structure and functions of eye, ear, nose and tongue and their disorders. UNITV 07 Hours • Endocrine system Classification of hormones, mechanism of hormone action, structure and functions of pituitary gland, thyroid gland, parathyroid gland, adrenal gland, pancreas, pineal gland, thymus and their disorders. Tutorials Teaching hours: 15 Hours Tutorials will be based on above syllabus Suggested Readings/\: (Latest Edition) 1. Sembulingam, K. Sembulingam , P. Essentials of Medical Physiology. New Delhi, Jaypee Brother's Medical Publishers. 2. Wilson, K.J.W. Anatomy and Physiology in Health and Illness. New York, Churchill Livingstone. 3. Best and Tailor. Physiological basis of Medical Practice. MI USA, Williams & Wilkins Co, Riverview. 4. Guyton, A.C, Hall J.E, Miamisburg, O.H. Text book of Medical Physiology. U.S.A. Elseveir Saunders. 5. Tortora G, Palmetto, G.A. Principles of Anatomy and Physiology. U.S.A. John Wiley & sons. 6. Singh I. Textbook of Human Histology. New Delhi, Jaypee Brother's Medical Publishers. 7. Ghai, C.L. Textbook of Practical Physiology. New Delhi. Jaypee Brother' s Medical 2 Publishers. 8. Srinageswari, K., Sharma, R. Practical workbook of Human Physiology. New Delhi, Jaypee Brother's Medical Publishers. 9. Chatterrje, C.C. Human Physiology (vol I and 2). Kolkata, Academic Publishers L= Lecture, T= Tutorial, P= Practical, C= Credit A this is not an exhaustive list (B.Pharm) (Semester- I) L T P C 3 1 4 Course Code BP102T Course Title Pharmaceutical Analysis I - Theory Scope: This course deals with the fundamentals of analytical chemistry and principles of electrochemical analysis of drugs Objectives: Upon completion of the course student shall be able to 1. Understand the principles of volumetric and electro chemical analysis 2. Carryout various volumetric and electrochemical titrations 3. Develop analytical skills Course Learning Outcomes (CLO): At the end of the course, students will be able to - 1. Understand the basics of different types of titrimetric methods. 2. Describe the principle, instrumentation and electrodes of various electro analytical methods 3. Analyze the different sources and types of the error 4. Prepare solutions of different strengths used in pharmaceutical field (Molar, Normal etc.) Syllabus: Teaching hours: 45 Hours UNIT-I 10 Hours • Pharmaceutical analysis- Definition and scope i) Different techniques of analysis ii) Methods of expressing concentration iii) Primary and secondary standards. iv) Preparation and standardization of various molar and normal solutions- Oxalic acid, sodium hydroxide, hydrochloric acid, sodium thiosulphate, sulphuric acid, potassium permanganate and eerie ammonium sulphate • Errors: Sources of errors, types of errors, methods of minimizing errors, accuracy, 3 precision and significant figures • Pharmacopoeia, Sources of impurities in medicinal agents, limit tests. UNIT-II 10 Hours • Acid base titration: Theories of acid base indicators, classification of acid base titrations and theory involved in titrations of strong, weak, and very weak acids and bases, neutralization curves • Non aqueous titration: Solvents, acidimetry and alkalimetry titration and estimation of Sodium benzoate and Ephedrine HCl UNIT-III 10 Hours • Precipitation titrations: Mohr's method , Volhard's, Modified Volhard's, Fajans method, estimation of sodium chloride. • Complexometric titration: Classification, metal ion indicators, masking and demasking reagents, estimation of Magnesium sulphate, and calcium gluconate. • Gravimetry: Principle and steps involved in gravimetric analysis. Purity of the precipitate: co-precipitation and post precipitation, Estimation of barium sulphate. • Basic Principles,methods and application of diazotisation titration. UNIT-IV 08 Hours • Redox titrations (a) Concepts of oxidation and reduction (b) Types ofredox titrations (Principles and applications) Cerimetry, Iodimetry, Iodometry, Bromatometry, Dichrometry, Titration with potassium iodate UNIT-V 07 Hours • Electrochemical methods of analysis • Conductometry- Introduction, Conductivity cell, Conductometric titrations, applications. • Potentiometry - Electrochemical cell, construction and working of reference (Standard hydrogen, silver chloride electrode and calomel electrode) and indicator electrodes (metal electrodes and glass electrode), methods to determine end point of potentiometric titration and applications. • Polarography Principle, Ilkovic equation, construction and working of dropping mercury electrode and rotating platinum electrode, applications Tutorials Teaching hours: 15 Hours Tutorials will be based on above syllabus Suggested Readings/\: (Latest edition) 1. Beckett, A. H., & Stenlake, J. B. (Eds.). Practical Pharmaceutical Chemistry: Part I & II. A&C Black. 2. Mendham, J. Vogel's textbook of quantitative chemical analysis. Pearson Education India. 3. P. Gundu Rao, Inorganic Pharmaceutical Chemistry. Vallabh Publications. 4. Driver, J. E. Bentley & Driver's text-book of pharmaceutical chemistry. London. 5. Kennedy, J. H. Analytical Chemistry: Principles. Harcourt School. 6. Indian Pharmacopoeia L= Lecture, T= Tutorial, P= Practical, C= Credit " this is not an exhaustive list 4 (B. Pharm.) (Semester - I) L T P C 3 1 4 Course Code BP103T Course Title Pharmaceutics I - Theory Scope: This course is designed to impart a fundamental knowledge on the preparatory pharmacy with arts and science of preparing the different conventional dosage forms. Objectives: Upon completion of this course the student should be able to: 1. Know the history of profession of pharmacy 2. Understand the basics of different dosage forms, pharmaceutical incompatibilities and pharmaceutical calculations 3. Understand the professional way of handling the prescription 4. Preparation of various conventional dosage forms Course Learning Outcomes (CLO): At the end of the course, students will be able to - 1. Discuss history of pharmacy profession and various dosage forms 2. Explain various conversions systems used in pharmaceutical dispensing 3. Understand the concepts of dispensing methods for various dosage forms 4. Interpret types of prescriptions and study their handling 5. Solve pharmaceutical calculations and pharmaceutical incompatibilities related to dispensing of products 6. Prepare various types of dispensed products at small scale
Load more

Recommended publications
  • House Bill No. 2191
    SECOND REGULAR SESSION HOUSE BILL NO. 2191 99TH GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE QUADE. 5582H.01I D. ADAM CRUMBLISS, Chief Clerk AN ACT To repeal section 579.060, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Section 579.060, RSMo, is repealed and one new section enacted in lieu 2 thereof, to be known as section 579.060, to read as follows: 579.060. 1. A person commits the offense of unlawful sale, distribution, or purchase of 2 over-the-counter methamphetamine precursor drugs if he or she knowingly: 3 (1) Sells, distributes, dispenses, or otherwise provides any number of packages of any 4 drug product containing detectable amounts of ephedrine, levomethamphetamine, 5 phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any of their salts, optical 6 isomers, or salts of optical isomers, in a total amount greater than nine grams to the same 7 individual within a thirty-day period, unless the amount is dispensed, sold, or distributed 8 pursuant to a valid prescription; or 9 (2) Purchases, receives, or otherwise acquires within a thirty-day period any number of 10 packages of any drug product containing any detectable amount of ephedrine, 11 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any 12 of their salts or optical isomers, or salts of optical isomers in a total amount greater than nine 13 grams, without regard to the number of transactions, unless the amount is purchased, received, 14 or acquired pursuant to a valid prescription; or 15 (3) Purchases, receives, or otherwise acquires within a twenty-four-hour period any 16 number of packages of any drug product containing any detectable amount of ephedrine, 17 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • FDA Warns That Abuse and Misuse of the Nasal Decongestant Propylhexedrine Causes Serious Harm This Includes Heart and Mental Health Problems Or Death
    FDA warns that abuse and misuse of the nasal decongestant propylhexedrine causes serious harm This includes heart and mental health problems or death 3-25-2021 FDA Drug Safety Communication What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that the abuse and misuse of the over- the-counter (OTC) nasal decongestant propylhexedrine can lead to serious harm such as heart and mental health problems. Some of these complications, which include fast or abnormal heart rhythm, high blood pressure, and paranoia, can lead to hospitalization, disability, or death. Reports of individuals abusing and misusing propylhexedrine have increased in recent years. Propylhexedrine is safe and effective when used as directed. What is FDA doing? We are requesting that all manufacturers of OTC propylhexedrine nasal decongestant inhalers consider product design changes that support its safe use. For example, modifying the product to create a physical barrier that would make tampering with the device and abusing the propylhexedrine inside more difficult. In addition, decreasing the amount of medicine the device contains could also reduce the risk of serious side effects if abused or misused. We continue to evaluate this safety issue and will determine if additional FDA actions are needed. What is propylhexedrine and how can it help me? Propylhexedrine is a nasal decongestant that is available OTC in an inhaler. It is used short term to temporarily relieve nasal congestion due to colds, hay fever, or other upper respiratory allergies. It works by reducing swelling and inflammation of the mucous membrane lining of the nose.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Whoexpertcommittee Ondrugdependence
    Thisreportcontainsthecollectiveviewsof an international groupof expertsanddoesnotnecessarilyrepresentthedecisions Tile World 1lealth Organization is a specialized agcncyof the United Nations with orthestatedpolicyof theWorldHealthOrganization primary responsibility for international health'matters anti public health. Through this organization, which was created in 1948, the health professions of' some I65 countries exchange their knowledge and experience with the aim of making possible will permit them lo lead a socially and ccommlically productive lil_. WHOExpertCommittee By means of direct technical cooperation whh its Membcr Stales, and by stimt,- hhensiveding suchhealthcooperationservices, tamonghe preventionthem, WllOprornotesthcdevclopmcntorcomprc-anti control of diseascs, thc improvement o[ environmental conditions, tile development of health manpower, the coordination onDrugDependence anti development of biomedical and health services research, and thc planning and implementation of health programmes. These broad fiekls of endeavour encompass a wide variety of activities, such as developing systems of primary health cltre that reach the whole population of Mem- ber countries; promoting tile health of`mothers and children; combating malnutrition; controlling malaria and other communicable diseases including tuberculosis and leprosy; having achieved tile eradication or smallpox, promoting mass immunization against a numbcr of other preventable diseases; improving mental health; providing safe water supplies: anti training health
    [Show full text]
  • First Steps Towards a Floral Structural Characterization of the Major Rosid Subclades
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2006 First steps towards a floral structural characterization of the major rosid subclades Endress, P K ; Matthews, M L Abstract: A survey of our own comparative studies on several larger clades of rosids and over 1400 original publications on rosid flowers shows that floral structural features support to various degrees the supraordinal relationships in rosids proposed by molecular phylogenetic studies. However, as many apparent relationships are not yet well resolved, the structural support also remains tentative. Some of the features that turned out to be of interest in the present study had not previously been considered in earlier supraordinal studies. The strongest floral structural support is for malvids (Brassicales, Malvales, Sapindales), which reflects the strong support of phylogenetic analyses. Somewhat less structurally supported are the COM (Celastrales, Oxalidales, Malpighiales) and the nitrogen-fixing (Cucurbitales, Fagales, Fabales, Rosales) clades of fabids, which are both also only weakly supported in phylogenetic analyses. The sister pairs, Cucurbitales plus Fagales, and Malvales plus Sapindales, are structurally only weakly supported, and for the entire fabids there is no clear support by the present floral structural data. However, an additional grouping, the COM clade plus malvids, shares some interesting features but does not appear as a clade in phylogenetic analyses. Thus it appears that the deepest split within eurosids- that between fabids and malvids - in molecular phylogenetic analyses (however weakly supported) is not matched by the present structural data. Features of ovules including thickness of integuments, thickness of nucellus, and degree of ovular curvature, appear to be especially interesting for higher level relationships and should be further explored.
    [Show full text]
  • INTRODUCTION Revisions for Thailand of the Genera Now
    THAI FOR. BULL. (BOT.) 43: 46–50. 2015. Revisiting taxonomic circumscriptions in Hydnocarpus Gaertn. and Ryparosa Blume for the Achariaceae of Thailand BRUCE L. WEBBER1 & BOB HARWOOD2 ABSTRACT. The split of the Flacourtiaceae into Achariaceae and Salicaceae has necessitated an updated treatment of these families for regional fl oras. In revising the Achariaceae for the Flora of Thailand, new insights on taxon circumscriptions in the family were generated based on a robust interrogation of delimiting characters and historical taxonomic decisions. Justifi cations for accepting certain taxa and synonymising others are here presented, along with recommendations for guiding future taxonomic work. KEY WORDS: Achariaceae, delimiting characters, Flacourtiaceae, Hydnocarpus, Ryparosa, Hermann Sleumer, Thailand. INTRODUCTION (e.g. Ryparosa fasciculata King and Ryparosa scortechinii King), and characterise important Revisions for Thailand of the genera now morphological differences between species (Sleumer, included in Achariaceae have often lagged behind 1954), do not appear to hold when subjected to current circumscriptions at both the family and closer scrutiny, particularly when applying fi eld- species levels. The most recent regional revision based knowledge of the species in question. To covering the 11 genera that were once placed in complement the revision of Achariaceae for the Flacourtiaceae is now 30 years old (Sleumer, 1985). Flora of Thailand (Harwood & Webber, 2015), here Since then, Chase et al. (2002) concluded that there we revisit species from two of the four genera in was no justifi cation for maintaining Flacourtiaceae, Thailand – Hydnocarpus and Ryparosa – providing and placed the majority of genera in either Salicaceae detailed notes on the justifi cation behind our taxo- or Achariaceae.
    [Show full text]
  • 2008 Prohibited List
    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
    [Show full text]